We demonstrate here the feasibility and efficacy of this approach by showing that increased expression of SEC23A using CRISPRa rescues the SEC23B-deficient erythroid defect, suggesting a novel strategy to treat CDAII. Here, SEC23A is linked to Congenital dyserythropoietic anemia type II.